Belpomme D, Marty M, Gisselbrecht C, Mignot L, Pujade-Lauraine E
Pathol Biol (Paris). 1981 Mar;29(3):179-88.
Immunotherapy is still considered as an important therapeutic method in oncology. Experimental basis do exist which support the individualization of several distinct conditions of immunomodulation, some of them being associated with a therapeutic benefit. Numerous immunomodulation molecules or derivatives are now available for clinical investigations. However, effects of immunomodulators on the immune systems which depend on several unknown factors are actually not always fairly correlated with antitumoral treatment. The authors review here the available data obtained from recent clinical studies in man. They attempt to establish the limits of immunotherapy as well as its future possibilities.
免疫疗法在肿瘤学中仍被视为一种重要的治疗方法。确实存在支持几种不同免疫调节状况个体化的实验依据，其中一些与治疗益处相关。现在有许多免疫调节分子或衍生物可用于临床研究。然而，免疫调节剂对免疫系统的影响实际上并不总是与抗肿瘤治疗有相当好的相关性，这取决于几个未知因素。作者在此回顾了从最近人体临床研究中获得的现有数据。他们试图确定免疫疗法的局限性及其未来可能性。
